Health Care [ 9/12 ] | Biotechnology [ 38/73 ]
NASDAQ | Common Stock
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.
Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products.
The company was founded in 2019 and is based in Naples, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | 1.99 M Increased by +307.74% | Increased by +N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -2.51 M Decreased by -716.94% | Decreased by N/A% - |
| Mar 31, 23 | 0.00 - | -2.17 M - | Decreased by N/A% - |
| Dec 31, 22 | 0.00 - | -3.07 M - | Decreased by N/A% - |
| Sep 30, 22 | 0.00 - | -956.00 K - | Decreased by N/A% - |
| Mar 31, 22 | N/A - | -307.00 K - | - - |